Key result
Betrixaban requires further post-marketing data to clarify its clinical performance for VTE prophylaxis.
Why the study?
A substantial volume of data is needed to dispel uncertainties surrounding betrixaban for VTE thromboprophylaxis following its approval by the FDA but non-approval by the EMA.
Betrixaban is an FDA-approved direct factor Xa inhibitor for VTE prophylaxis that lacks EMA approval, highlighting the need for post-marketing pharmacovigilance data to clarify its safety and efficacy profile.
Betrixaban's FDA-only approval warrants selective prescribing; leaves open its comparative safety and efficacy pending post-marketing data.
Venous thromboembolism (VTE), comprising deep-vein thrombosis (DVT) and pulmonary embolism (PE), stands as the third leading cause of vascular-related mortality on a global scale. Anticoagulation prophylaxis undeniably ensures a significant reduction in the risk of DVT, while simultaneously exposing individuals to an elevated likelihood of experiencing both major and minor bleeding events. Betrixaban is a novel oral anticoagulant, a direct factor Xa inhibitor, approved by the Food and Drug Administration (FDA) but not by the European Medicines Agency (EMA) for VTE thromboprophylaxis. The current necessity revolves around the acquisition of a substantial volume of data to dispel the uncertainties associated with this drug due to its non-approval by the EMA. Consequently, we eagerly await the results of post-marketing pharmacovigilance efforts to provide further insights into the performance of betrixaban within the broader population.
No takes yet. Share an insight, caveat, or question.
Caturano et al. (2023) conducted a review in Venous thromboembolism (VTE). Betrixaban was evaluated. Betrixaban, a direct factor Xa inhibitor approved by the FDA but not the EMA for VTE prophylaxis, requires further post-marketing pharmacovigilance data to clarify its clinical performance.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: